Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
0.00%
)
Bitcoin
74,074.52
(
0.43%
)
News Focus
News Focus
Post# of 257661
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123040
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: drbio45 post# 42476

Monday, 02/26/2007 2:52:39 PM

Monday, February 26, 2007 2:52:39 PM

Post# of 257661
Re: Galvus

>too bad Novartis tried to show how safe their drug was at 30 time the dose and Merck only cared about 3 times the dose. Sometime too much information, is too much information<

If NVS’ own statements today are to be believed, the approvable letter is not due to the skin lesions seen in monkeys but rather to renal clearance.

p.s. Interesting color on the diabetes market—thanks for posting.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today